Neurocrine Signs US$1.7 B Epilepsy Pact with Xenon
By Michelle Liu
Pharma Deals Review: Vol 2019 Issue 12 (Table of Contents)
Published: 10 Dec-2019
DOI: 10.3833/pdr.v2019.i12.2475 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
In its second deal of 2019, Neurocrine Biosciences has entered into a license and collaboration agreement with Xenon Pharmaceuticals to discover, develop and commercialise sodium channel inhibitors for the treatment of epilepsy...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS